Business
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expected to Begin Patient Enrollment in the Near Future Licensed GMP-Ready Pharmaceutical Facility for Botanical and Synthetic Psilocybin Manufacturing Creates Strategic Commercialization Advantage Milestone-Based Structure Provides Significant Additional Long-Term Value Creation RAMAT GAN, ISRAEL, April
About this update from Xtl Biopharmaceuticals Ltd.
[{"type":"image","alt":"XTL Biopharmaceuticals Ltd.","displaySize":"","headline":null,"caption":"XTL Biopharmaceuticals Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":191,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/ec9b45c6e485e8fa9ea9e6572969aa56"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hYIhqXLT8lt_CG_gVDzVwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwOQ--/https://media.zenfs.com/en/globenewswire.com/ec9b45c6e485e8fa9ea9e6572969aa56","width":191,"height":58}},"lazy":false},{"type":"text","content":"Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum","length":147,"tagName":"p"},{"type":"text","content":"Seven Approved Phase 2a Human Clinical Trials Expected to Begin Patient Enrollment in the Near Future","length":101,"tagName":"p"},{"type":"text","content":"Licensed GMP-Ready Pharmaceutical Facility for Botanical and Synthetic Psilocybin Manufacturing Creates Strategic Commercialization Advantage","length":141,"tagName":"p"},{"type":"text","content":"Milestone-Based Structure Provides Significant Additional Long-Term Value Creation","length":82,"tagName":"p"},{"type":"text","content":"RAMAT GAN, ISRAEL, April 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) to acquire 100% of the issued and outstanding share capital of Psyga Bio Ltd., (the “Psyga”), an advanced biotechnology company focused on the research, development and commercialization of proprietary products derived from psychedelic and functional mushrooms, including clinically researched therapeutic candidates, microdosing solutions and wellness-focused formulations..","length":588,"tagName":"p"},{"type":"text","content":"Psyga operates a licensed, GMP-ready pharmaceutical manufacturing facility designed for the cultivation, extraction, isolation, formulation and production of pharmaceutical-grade botanical and synthetic psilocybin, Ibogaine and other psychedelic active pharmaceutical ingredients (APIs), in accordance with applicable international pharmaceutical manufacturing standards. It has developed a proprietary library of more than 180 unique mushroom strains, including differentiated high-potency and b...